Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

93957-54-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 6-Heptenoic acid,7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-,(3R,5S,6E)-rel- 93957-54-1

    Cas No: 93957-54-1

  • No Data

  • 1 Kilogram

  • 10000 Metric Ton/Month

  • Shanghai Upbio Tech Co.,Ltd
  • Contact Supplier

93957-54-1 Usage


Fluvastatin, also known as Lescol, is a synthetic HMG-CoA reductase inhibitor that is structurally similar to pravastatin. It features a heptanoic acid side chain that can be superimposed over the lactone ring found in lovastatin and simvastatin, which is recognized by HMG-CoA reductase. Due to its structural design, fluvastatin has lower CNS side effects compared to other lipid-lowering agents with a lactone ring.


Used in Pharmaceutical Industry:
Fluvastatin is used as a lipid-lowering agent for reducing high cholesterol levels in the blood. It works by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis, thus helping to lower LDL (bad) cholesterol and triglycerides while increasing HDL (good) cholesterol.
Used in Cardiovascular Disease Management:
Fluvastatin is used as a preventive medication for cardiovascular diseases, such as coronary artery disease, heart attacks, and strokes. By reducing cholesterol levels, it helps to prevent the formation of plaques in the arteries, which can lead to these conditions.
Used in Research Applications:
Fluvastatin is also used in research settings to study the effects of HMG-CoA reductase inhibition on various biological processes, such as cholesterol synthesis, cell growth, and inflammation. This helps in understanding the underlying mechanisms of cholesterol regulation and its role in various diseases.


Lipaxan, Italfarmaco spa

Manufacturing Process

164 ml (235.1 g, 2.04 moles) of chloroacetyl chloride is added over a 50 min period to a mixture of 400 ml (410 g, 4.22 moles) of fluorobenzene and 300.0 g (2.25 moles) of anhydrous aluminum chloride stirred at 75°C under nitrogen. The reaction mixture is stirred at 80°C under nitrogen for 1 h, cooled to 50°C, 500 ml of fluorobenzene is added, and the reaction mixture is cooled to 0°C and gradually (over a 30 min period) siphoned into 1 L of 6 N hydrochloric acid stirred at 0°C. (The temperature of the aqueous acid is maintained at or below 25°C throughout the addition). The quenched, acidified reaction mixture is stirred for 15 min, and the aqueous phase is separated and extracted with 350 ml of fluorobenzene. The two organicphases are combined and washed twice with 500 ml portions of 3 N hydrochloric acid and once with 500 ml of water. The fluorobenzene is distilled at 30 mm. Hg and 60°C and, upon cooling, the obtained 4-chloroacetyl-1fluorobenzene oily residue solidifies.562.9 g (4.08 moles) of N-isopropylaniline is rapidly added to a solution of the 4-chloroacetyl-1-fluorobenzene in 500 ml of dimethylformamide stirred at 50°C under nitrogen. The reaction mixture is stirred at 100°C under nitrogen for 10 h and allowed to cool to room temperature overnight. The reaction mixture is heated to 60°C, 2 L of water is added, and the mixture is cooled to 10°C. The obtained solids are collected, washed twice with 500 ml portions of water and dissolved in 550 ml of 95% ethanol at 75°C. The solution is cooled to 0°C, and the obtained solids are collected, washed three times with 100 ml portions of 95% ethanol and vacuum dried at 35°-40°C for 4 h to obtain the 95.3% pure yellow product: N-(4-fluorobenzoylmethyl)-N-(1-methylethyl) aniline (466.0 g, 84.2%, melting point 78° -81°C).4.5 ml of 1 N sodium hydroxide solution (4.5 mmol) and 2.0 g (4.7 mmol) of N-(4-fluorobenzoylmethyl)-N-(1-methylethyl)aniline are stirred in 150 ml of ethanol at room temperature for 2 h, the solvent is evaporated at reduced pressure, and the residue is dissolved in 50 ml of water. The aqueous solution is gently extracted with diethyl ether, the traces of ether in the aqueous layer are removed at reduced pressure, and the aqueous layer is freeze dried to obtain racemic sodium threo-(+/-)-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)1'-(1"-methylethyl )indol-2'-yl]hept-6-enoate (1.8 g (88%)), melting point 194°-197°C.The crude sodium threo-(+/-)-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-1'(1"-methylethyl )indol-2'-yl]hept-6-enoate is dissolved in water, and the solution is acidified to pH 2 with 2 N hydrochloric acid and extracted with diethyl ether. The diethyl ether extract is washed three times with saturated sodium chloride solution, dried over anhydrous magnesium sulfate and evaporated at reduced pressure to obtain the crude solid racemic erythro-(+/)-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-1'-(1"-methylethyl )indol-2'-yl] hept-6-enoic acid (6.9 g).The racemic erythro-(+/-)-(E)-3,5-dihydroxy-7-[3'-(4"-fluorophenyl)-1'-(1"methylethyl )indol-2'-yl]hept-6-enoic acid may both be resolved into two optically pure enantiomers, the 3R, 5S and 3S, 5R isomers by chromatography on silica gel column using organic solutions as the eluent.

Therapeutic Function


Clinical Use

HMG CoA reductase inhibitor:Primary hypercholesterolaemiaSlowing progression of atherosclerosisSecondary prevention of coronary events after percutaneous coronary intervention

Drug interactions

Potentially hazardous interactions with other drugs Antibacterials: rifampicin increases metabolism; increased risk of myopathy with daptomycin; avoid for 7 days after last dose of fusidic acid. Anticoagulants: anticoagulant effect enhanced. Antiepileptics: concentration of either or both drugs may be increased with fosphenytoin and phenytoin. Antifungals: concentration increased by fluconazole - increased risk of myopathy. Antivirals: possible increased risk of myopathy with ledipasvir - reduce fluvastatin dose; avoid with paritaprevir. Ciclosporin: concomitant treatment with ciclosporin may lead to risk of muscle toxicity. Colchicine: isolated cases of myopathy have been reported. Lipid-lowering drugs: increased risk of myopathy with gemfibrozil, fibrates and nicotinic acid - avoid with gemfibrozil.


Fluvastatin is rapidly and completely absorbed from the gastrointestinal tract and undergoes extensive firstpass metabolism in the liver. Metabolism is mainly by the cytochrome P450 isoenzyme CYP2C9, with only a small amount metabolised by CYP3A4. The major components circulating in the blood are fluvastatin and the pharmacologically inactive N-desisopropyl-propionic acid metabolite. The hydroxylated metabolites have pharmacological activity but do not circulate systemically. About 93% is excreted in the faeces, mainly as metabolites, with only about 6% being excreted in the urine

Check Digit Verification of cas no

The CAS Registry Mumber 93957-54-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,9,5 and 7 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 93957-54:
181 % 10 = 1
So 93957-54-1 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017


1.1 GHS Product identifier

Product name Fluvastatin

1.2 Other means of identification

Product number -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:93957-54-1 SDS

93957-54-1Upstream product

93957-54-1Downstream Products

93957-54-1Relevant articles and documents

Methods for predicting the response to statins


, (2011/10/13)

The invention provides methods for optimizing therapeutic efficacy for treating hypercholesterolemia in a subject having a cardiovascular disease (CVD), comprising (a) determining subject characteristics that affect the likelihood of reaching a goal level of low density lipoprotein (LDL); and (b) obtaining success probabilities of a variety of statin treatments for reaching said goal level of LDL using said subject characteristics and a multivariate model; and (c) administrating the optimal statin treatment with the highest success probability of step (b) to said subject thereby optimizing therapeutic efficacy for treating hypercholesterolemia in said subject.

Treatment of type 1 diabetes with PDE5 inhibitors


, (2008/06/13)

The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.

Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound


, (2008/06/13)

A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g., fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 93957-54-1